Figure 5.

Transfer of inhibition of the in vivo priming to p195–212 by splenocytes of dual APL-treated mice. (A) SJL mice were injected intraperitoneally with the dual APL (200 μg per mouse in PBS) seven times in 2-day intervals. Splenocytes obtained from these mice were injected intravenously (10 × 10⁶ cells per mouse in PBS) to SJL mice concomitantly with immunization with 10 μg of p195–212 in CFA (□). Alternatively, SJL mice were immunized with 10 μg of p195–212 in CFA only (■). A proliferation assay was performed as described in Materials and Methods. (B) SJL mice were injected intraperitoneally either with the dual APL (200 μg per mouse in PBS; □) or with PBS (■) seven times in 2-day intervals. Splenocytes were obtained from these mice and injected intravenously (20 × 10⁶ cells per mouse in PBS) to SJL mice concomitantly with immunization with 10 μg of p195–212 in CFA. A proliferation assay was performed as described in Materials and Methods.